JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kothny-Wilkes, G.
Right arrow Articles by Schwarz, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kothny-Wilkes, G.
Right arrow Articles by Schwarz, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 41, 28916-28921, October 8, 1999


Interleukin-1 Protects Transformed Keratinocytes from Tumor Necrosis Factor-related Apoptosis-inducing Ligand- and CD95-induced Apoptosis but Not from Ultraviolet Radiation-induced Apoptosis*

Gabriele Kothny-WilkesDagger , Dagmar KulmsDagger , Thomas A. LugerDagger , Marek Kubin§, and Thomas SchwarzDagger

From the Dagger  Ludwig Boltzmann Institute for Cell Biology and Immunobiology of the Skin, Department of Dermatology, University of Münster, Von-Esmarchstrasse 56, D-48149 Münster, Germany and § Immunex Corporation, Seattle, Washington 98101

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a new member of the tumor necrosis factor (TNF) family, induces apoptosis primarily of transformed cells. Interleukin-1 was previously found to protect the keratinocyte cell line KB from TRAIL-induced apoptosis, thus we studied whether interleukin-1 also protects from other apoptotic stimuli (ultraviolet radiation (UV), CD95-ligand). Interleukin-1 rescued KB cells from TRAIL- and CD95-induced apoptosis, which was critically dependent on nuclear factor kappa B, because cells transfected with a super-repressor form of the nuclear factor kappa B inhibitor Ikappa B were less protected. In contrast, UV-mediated apoptosis was not only not prevented by interleukin-1 but even enhanced. This opposite effect of interleukin-1 was also observed for the expression of the inhibitor of apoptosis proteins (IAP). Whereas TRAIL- and CD95-mediated suppression of IAP expression was partially reversed by interleukin-1, UV-mediated down-regulation of IAPs was not reversed but even further enhanced. Increased apoptosis induced by interleukin-1 plus UV was accompanied by excessive TNFalpha release, implying that enhanced cytotoxicity is due to the additive effect of these two apoptotic stimuli. Accordingly, enhanced apoptosis was reduced by blocking the TNF receptor-1. The opposite effects of interleukin-1 indicate that different mechanisms are involved in UV-induced apoptosis compared with CD95- and TRAIL-mediated apoptosis. Furthermore, the data suggest that whether a signal acts in an antiapoptotic way or not does not only depend on the signal itself but also on the stimulus causing apoptosis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

During apoptosis, a complex death program becomes initiated that ultimately leads to the fragmentation of the cell. The death program can be either initiated by the cell itself when the time has come to die (programmed cell death) or by certain external stimuli activating death receptors on the cell surface (for review, see Ref. 1). Thus, apoptosis does not only play an important role in the development and maintenance of tissue homeostasis but also represents an effective mechanism by which harmful cells can be eliminated. Induction of apoptosis allows the organism to get rid of infected cells and also of tumor cells. Accordingly, resistance to apoptosis was identified as an important event in tumorigenesis. Apoptosis of tumor cells can be initiated by triggering cell death receptors, leading to activation of the intracellular apoptotic machinery (2). Chemotherapeutic drugs used in cancer treatment may exert their therapeutic effects by activating these pathways (3-5). On the other hand, it is known that defects in the apoptotic pathways or activation of antiapoptotic machineries can confer resistance to chemotherapy (for review, see Refs. 6 and 7). In addition, tumor cells can escape apoptotic elimination by down-regulation of apoptosis-related molecules on the cell surface (8, 9). Consequently, control of the balance between pro- and antiapoptotic processes within the cell has been recognized as an important target for therapeutic intervention. Thus, elucidation of the molecular mechanisms regulating these processes is of primary interest.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),1 also called APO-2 ligand, is a recently identified molecule belonging to the tumor necrosis factor (TNF) family that was characterized by its ability to induce apoptosis (10, 11). Among the TNF family members, TRAIL displays highest homology to CD95-ligand (CD95L), which induces apoptosis by triggering the surface receptor CD95 (Fas/APO-1) (12). In contrast to CD95L, TRAIL was found to induce apoptosis in numerous transformed cell lines but to kill normal cells less effectively (10, 11). Because of the unique ability to induce apoptosis preferentially in cancer but not in normal cells, TRAIL may be highly efficient in specifically eradicating tumor cells in vivo (13). Thus, TRAIL has prospects of becoming an effective anticancer drug of the future. Recently, we observed that preincubation with the pro-inflammatory cytokine interleukin-1 (IL-1) renders transformed keratinocytes resistant to the apoptotic effect of TRAIL (14). The protective effect of IL-1 against TRAIL-induced apoptosis seems to be mediated via activation of the transcription factor nuclear factor kappa B (NFkappa B). The observation that transformed cells become resistant to TRAIL upon exposure to IL-1 was the first demonstration of a pathway that allows tumor cells to escape the killing effect of TRAIL. Because IL-1 is secreted by a variety of tumor cells (15) and is also released by inflammatory cells participating in the tumor-host immune response (16), tumors under these conditions could become resistant to TRAIL in vivo.

Therefore, we were interested in expanding these observations by studying whether the antiapoptotic effect of IL-1 is restricted to TRAIL or whether other apoptotic stimuli are inhibited as well. Here, we show that IL-1 protects transformed keratinocytes from TRAIL- and CD95-mediated apoptosis. In contrast, apoptosis induced by ultraviolet (UV) irradiation was not only not prevented by IL-1 but was even further enhanced. This opposite effect of IL-1 was also observed when studying the expression of the antiapoptotic proteins c-IAP1 and c-IAP2. Thus, these data suggest that antiapoptotic activity of a stimulus does not only depend on its nature but also on the stimulus causing apoptosis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells-- The epitheloid carcinoma cell line KB (American Type Culture Collection, Manassas, VA) and the spontaneously transformed human keratinocyte cell line HaCaT (kindly provided by N. Fusenig, Deutsches Krebsforschungszentrum, Heidelberg, Germany) (17) were cultured in RPMI containing 10% fetal calf serum and 1% glutamine at 37 °C with 5% CO2 in a humidified atmosphere. Irradiation of cells with UV light was performed using a bank of 4 FS20 bulbs (Westinghouse Electric Corp., Pittsburgh, PA) which emit most of their energy within the UVB range (290-320 nm) with an emission peak at 313 nm as described (18). Subconfluent cells were exposed through PBS to a dose of 300 J/m2, unless otherwise stated.

Reagents-- Recombinant human TRAIL protein was provided from Immunex Corp., Seattle, WA. This is a leucine zipper form of TRAIL that requires no further cross-linking for induction of maximal apoptotic acitivity (19). Recombinant CD95L and an agonistic antibody against CD95 (CD95-Ab) were obtained from Alexis and Immunotech, respectively. Antibodies directed against caspase-3 and poly(ADP-ribose) polymerase (PARP) were obtained from Dianova, Hamburg and Roche Molecular Biochemicals, Mannheim, Germany, respectively. Antibodies directed against c-IAP1, c-IAP2, and the fluorescein isothiocyanate-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Recombinant human IL-1beta was obtained from Roche Molecular Biochemicals. TNFalpha was measured by use of an ultrasensitive TNFalpha enzyme-linked immunosorbent assay (Diaclone, Besancon, France). Plasmids allowing overexpression of a mutated Ikappa B variant were kindly provided by K. Schulze-Osthoff, Münster, Germany (20).

Detection of Cell Death-- For the detection of DNA fragmentation, a cell death detection enzyme-linked immunosorbent assay (Roche Molecular Biochemicals) was used. The enrichment of mono- and oligonucleosomes released into the cytoplasm is calculated using the formula: absorbance of sample cells/absorbance of control cells. Enrichment factor was used as a parameter of apoptosis and shown on the y axis as mean ± S.D. of triplicates.

Quantitation of apoptosis by annexin V binding was performed using a commercially available kit (Bender Corp., Vienna, Austria). Briefly, cells were washed and resuspended in annexin V binding buffer. Fluorescein isothiocyanate-conjugated annexin V was added, and the samples were analyzed by flow cytometry (Epics XL, Coulter, Miami, FL).

Western Blot Analysis-- Cells were harvested and lysed in RIPA buffer (10 mM Tris, pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 4 µg/ml aprotinin, 1 mM sodium orthovanadate) for 15 min on ice. After centrifugation, supernatants were collected, and the protein content measured using a Bio-Rad Protein Assay kit (Bio-Rad). Protein samples were subjected to SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membranes, and incubated with antibodies of interest. To monitor equal loading, membranes were reprobed with an antibody directed against alpha -tubulin (Pharmingen, San Diego, CA). Signals were detected with an ECL kit (Amersham Pharmacia Biotech, Buckinghamshire, UK).

Transfection-- Cells (1.5 × 107) were washed once with PBS and resuspended in 600 µl of PBS, 1.25% Me2SO. Cells were electroporated with 20 µg of each plasmid DNA according to the method described by Melkonyan et al. (21). Transfection efficiency of cells cotransfected with a plasmid encoding beta -galactosidase (pcDNA6/VS-His/lacZ; Invitrogen, San Diego, CA) was determined 24 h later by staining with X-gal (100 µg/ml) in 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mM MgCl2 in PBS.

Staining of Intracellular Proteins-- Aliquots of cells (2 × 105) were harvested 16 h after stimulation, washed once with PBS, and fixed with 0.8% paraformaldehyde for 5 min on ice. After washing, cells were treated with 0.3% saponine for 5 min on ice. Following centrifugation cells were incubated with the antibodies directed against c-IAP1 or c-IAP2 in 0.3% saponine at 4 °C overnight. Purified goat IgG was used as an isotype control. None of the stimuli used (TRAIL, CD95-Ab, UV radiation, IL-1) changed the isotype controls. Cells were washed with PBS and incubated with the respective fluorescein isothiocyanate-conjugated secondary antibody in 0.3% saponine for 30 min. Cells were washed, resuspended in 0.03% saponine/PBS, and subsequently analyzed in a flow cytometer.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

IL-1 Protects Transformed Keratinocytes from TRAIL- and CD95-induced Apoptosis but Not from UV-induced Apoptosis-- Because we had recently observed that IL-1 protects cells from TRAIL-induced apoptosis (14) we were interested in studying whether this effect is specific for TRAIL or whether IL-1 also protects cells from other apoptotic stimuli. Therefore, KB cells were exposed to TRAIL or to an agonistic CD95-Ab, which induces apoptosis via activation of CD95 (12). Both TRAIL and CD95-Ab induced apoptotic cell death of KB cells, as determined by a cell death detection enzyme-linked immunosorbent assay (Fig. 1). When KB cells were preincubated with IL-1 for 15 min, cells were almost completely protected from the apoptotic effect of both TRAIL and the CD95-Ab. Similar data were obtained with HaCaT cells or when annexin V staining was used as a read-out system for apoptosis (data not shown). Thus, these data indicate that IL-1 rescues cells from TRAIL-mediated as well as from CD95-mediated apoptosis. Similar observations were obtained when instead of the CD95-Ab recombinant CD95L was used as the apoptotic stimulus (data not shown).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   IL-1 protects from TRAIL- and CD95-induced apoptosis but not from UV-induced apoptosis. KB cells were exposed to TRAIL (32 ng/ml), CD95-Ab (1 µg/ml), or UV light (300 J/m2) in the absence or presence of recombinant human IL-1beta (10 ng/ml). Control cells (Co) were left untreated. Apoptosis was examined 16 h later by determining nucleosomal DNA fragmentation using an apoptosis determination kit. The rate of apoptosis is reflected by the enrichment of nucleosomes in the cytoplasm shown by the values on the y axis. Data presented show the representative results of one of three independently performed experiments.

We next investigated whether IL-1 also protects KB cells from UV-mediated apoptosis. Therefore, KB cells were exposed to 300 J/m2 in the absence or presence of IL-1 and apoptosis determined 16 h later. In contrast to CD95- and TRAIL-mediated apoptosis, prestimulation of KB cells with IL-1 did not protect cells from UV-induced apoptosis and even caused pronounced enhancement of cell death (Fig. 1). To exclude that the failure of IL-1 to rescue cells from UV-induced apoptosis is simply due to the fact that the dose of 300 J/m2 represents a too severe insult to the cells, lower UV doses were tested. As shown in Fig. 2, UV irradiation induced apoptosis in a dose-dependent manner, and in all cases IL-1 enhanced the apoptotic response.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   IL-1 enhances UV-induced apoptosis independently of the UV dose. KB cells were exposed to various doses of UV radiation (100, 200, or 300 J/m2) in the absence or presence of IL-1beta (10 ng/ml). Cells were stained 16 h later with fluorescein isothiocyanate-conjugated annexin V and subjected to flow cytometry analysis. Histograms show fluorescence intensity (x axis) versus cell number (y axis).

Caspase-3 is a member of the family of interleukin-1beta converting enzyme proteases that is involved in CD95-, TRAIL-, and UV-mediated cell killing (22-25). For activation, caspase-3 must be cleaved from its 32-kDa proform into its 17-kDa active form (26). Thus, caspase-3 cleavage can serve as an additional read-out system to evaluate apoptosis. Therefore, KB cells were exposed to TRAIL, CD95-Ab, or to UV light either in the absence or presence of IL-1. Cell lysates were prepared 16 h later for Western blot analysis using an antibody against caspase-3. Because this antibody is directed against the caspase-3 proform, it cannot recognize the processed 17-kDa form, and a loss of the immunoreactive band in samples in which caspase-3 is activated can be observed. Significant reduction of the caspase-3 proform was observed in protein extracts of KB cells that were treated either with TRAIL, CD95-Ab, or UV light (Fig. 3). Preincubation of cells with IL-1 almost completely prevented TRAIL- and CD95-induced caspase-3 activation. In contrast, IL-1 enhanced UV-induced caspase-3 activation, which is shown by the complete disappearance of the immunoreactive band.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   IL-1 differentially affects cleavage of caspase-3 and PARP. KB cells were exposed to TRAIL (32 ng/ml) (lanes 2 and 3), CD95-Ab (1 µg/ml) (lanes 4 and 5), or UV radiation (300 J/m2) (lanes 6 and 7) in the absence (lanes 1, 2, 4, and 6) or presence (lane 3, 5, and 7) of 10 ng/ml IL-1beta . Control cells were left untreated (lane 1). Proteins were extracted 16 h after treatment, and Western blot analysis was performed using antibodies directed against caspase-3, PARP, or alpha -tubulin.

Caspase-3 cleaves the death substrate PARP (27). Accordingly, PARP was cleaved from its intact 116-kDa form into the inactive 85-kDa fragment in samples of TRAIL-, CD95-Ab-, and UV-exposed KB cells (Fig. 3). IL-1 pretreatment significantly reduced TRAIL- and CD95-Ab-induced PARP cleavage, whereas UV-mediated cleavage of PARP was again enhanced in the presence of IL-1. Taken together, these data clearly demonstrate that IL-1 rescues cells from CD95- and TRAIL-induced apoptosis, whereas UV-induced apoptosis is even enhanced by IL-1.

The Protective Effect of IL-1 Is Critically Dependent on NFkappa B-- We recently proposed that IL-1 might rescue cells from TRAIL-induced apoptosis via activation of NFkappa B, because IL-1 activated NFkappa B in KB cells. Furthermore, inhibition of NFkappa B activation by the proteasome inhibitor MG132 antagonized the protective effect of IL-1 (14). Activation of NFkappa B is associated with degradation of the inhibitory protein Ikappa B by the proteasome pathway. Upon triggering of the IL-1 receptor, Ikappa B becomes phosphorylated at the serine residues 32 and 36, which acts as a signal for ubiquination and subsequent degradation of Ikappa B by the 26 S proteasome (28, 29). Thus, Ikappa B degradation and consequently NFkappa B activation can be blocked by proteasome inhibitors such as MG132 or lactacystin (29). However, the approach using proteasome inhibitors provides only indirect evidence that the protective effect of IL-1 is due to activation of NFkappa B, because one cannot exclude that the inhibitors like MG132 may affect other pathways as well. Thus, we addressed whether IL-1 protects KB cells from TRAIL- and CD95-mediated apoptosis via activation of NFkappa B by overexpressing a super-repressor form of Ikappa B. In this mutant form, two point mutations (Ser-32 right-arrow Ala, Ser-36 right-arrow Ala) prevent phosphorylation and subsequent proteasomal degradation of Ikappa B (20). As a consequence, NFkappa B release, nuclear translocation, and functional DNA binding is prevented. Whereas KB cells transfected with the empty cytomegalovirus vector were still rescued by IL-1, the protective effect of IL-1 on TRAIL- and CD95-induced apoptosis was significantly reduced in cells transfected with the Ikappa B super-repressor (Fig. 4). These results support the concept that IL-1-mediated protection from TRAIL- and CD95-induced apoptosis is dependent on NFkappa B activation.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   IL-1 protects from TRAIL- and CD95-induced apoptosis via activation of NFkappa B. KB cells were transiently transfected with a plasmid allowing overexpression of the super-repressor form of the NFkappa B inhibitor Ikappa B (pRc Ikappa B D/N) or with the empty control vector (pRc CMV) only. Cells were stimulated with TRAIL (32 ng/ml) or CD95-Ab (0.4 µg/ml) in the absence or presence of IL-1beta (10 ng/ml) 30 h after transfection. Control cells (Co) were left untreated. Apoptosis was examined 16 h after treatment by determining nucleosomal DNA fragmentation using an apoptosis determination kit. The rate of apoptosis is reflected by the enrichment of nucleosomes in the cytoplasm shown by the values on the y axis. Data presented show the representative results of one of three independently performed experiments.

Differential Regulation of Antiapoptotic Proteins by IL-1-- Because IL-1 protected KB cells from CD95- and TRAIL-induced apoptosis but enhanced UV-mediated cell death, we were interested in elucidating the mechanism underlying this heterogenous effect. It has recently been reported that NFkappa B may exert its antiapoptotic effect via induction of several proteins including the inhibitor of apoptosis proteins (IAP) c-IAP1 and c-IAP2 (30). Therefore we investigated how IL-1 affects c-IAP1 and c-IAP2 expression in KB cells exposed to the different apoptotic stimuli. Intracellular protein expression evaluated by fluorescence-activated cell sorter analysis revealed that KB cells express c-IAP1 and c-IAP2 constitutively (Fig. 5). Exposure of KB cells to either TRAIL, CD95-Ab, or UV light caused a down-regulation of both c-IAP proteins. IL-1 alone only marginally enhanced constitutive c-IAP1 and c-IAP2 expression (data not shown), but reversed CD95- and TRAIL-induced down-regulation of c-IAP1 and c-IAP2 partially (Fig. 5). The opposite effect was exerted by IL-1 when cells were exposed to UV light. In this case, IL-1 did not reverse reduced c-IAP1 and c-IAP2 protein levels, but even slightly further enhanced the down-regulation. Taken together, IL-1 appears to affect c-IAP levels differentially depending on the stimulus that induces apoptosis. The further reduction of c-IAP expression in UV-exposed cells by IL-1 might be an explanation why IL-1 enhances UV-induced apoptosis.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   IL-1 differentially affects expression of c-IAP1 and c-IAP2. KB cells were treated with TRAIL (32 ng/ml), CD95-Ab (1 µg/ml), or UV light (300 J/m2) in the absence or presence of IL-1beta (10 ng/ml). Control cells (Co) were left untreated. Cells were fixed 16 h later, permeabilized, and incubated with antibodies against c-IAP1 or c-IAP2. After incubation with fluorescein isothiocyanate-conjugated secondary antibodies, cells were subjected to flow cytometry. Purified IgG was used as an isotype control. Histograms show fluorescence intensity (x axis) versus cell number (y axis). Mean fluorescence intensity (MFI) is indicated in each graph. Data presented show representative results of one of three independently performed experiments.

Enhancement of UV-induced Apoptosis by IL-1 Is Due to Endogenous Release of TNFalpha -- TNFalpha can generate two types of signals, one that induces apoptosis (31) and one that activates NFkappa B (32). The overall result in a specific cell type under specific conditions appears to be dependent on the balance of the two signals (32). When KB cells were treated with TNFalpha in addition to TRAIL, an enhancement of apoptosis was observed (data not shown), indicating that under these conditions the death signal caused by TNFalpha overrules activation of NFkappa B. Consequently, both stimuli induce apoptosis in an additive way. Because TNFalpha can be released by KB cells (18) we looked into whether the enhancing effect of IL-1 on UV-induced apoptosis might be due to autocrine release of TNFalpha . To address this issue, KB and HaCaT cells, respectively, were exposed to TRAIL, CD95-Ab, or UV radiation in the absence or presence of IL-1. KB and HaCaT cells did not constitutively release TNFalpha . IL-1, TRAIL, or CD95-Ab alone or in any combination induced TNFalpha secretion only marginally. whereas UV irradiation induced moderate release of TNFalpha . In contrast, when cells were stimulated with UV light plus IL-1, dramatically enhanced TNFalpha release was observed (Table I). To substantiate that TNFalpha released under these conditions is involved in the enhanced induction of apoptosis, an antibody neutralizing the TNF receptor type 1 which mediates apoptosis (34) was used. Preincubation with the antibody caused a complete loss of the enhancing effect of IL-1 on UV-induced apoptosis (Fig. 6). This indicates that increased apoptosis of UV-exposed KB and HaCaT cells in the presence of IL-1 is due to the autocrine release of TNFalpha , which then enhances apoptosis.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Exposure of keratinocytes to IL-1 and UV radiation results in excessive release of TNFalpha
16 h after stimulation, supernatants were collected and TNFalpha levels were measured with an enzyme-linked immunosorbent assay.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Enhancement of UV-induced apoptosis by IL-1 is inhibited by blocking the TNF receptor type 1. KB and HaCaT cells, respectively, were exposed to UV radiation (300 J/m2) in the absence or presence of IL-1beta (10 ng/ml). An antibody blocking the TNF receptor type 1 was added (500 ng/ml). Apoptosis was examined 16 h after treatment by determining nucleosomal DNA fragmentation using an apoptosis determination kit. The rate of apoptosis is reflected by the enrichment of nucleosomes in the cytoplasm shown by the values on the y axis. Data presented show the representative results of one of three independently performed experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recently, IL-1 was shown to protect tumor cells from the apoptotic effect of TRAIL (14). Because IL-1 can be released by a variety of tumor cells (15) and is also released by inflammatory cells participating in the tumor-host immune response (16), cancer cells under these conditions may escape the possible therapeutic effect of TRAIL. In this study, we demonstrate that IL-1 does not only protect transformed cells from TRAIL- but also from CD95-mediated apoptosis. This effect of IL-1 is clearly due to activation of NFkappa B, because inhibition of NFkappa B by overexpression of a dominant negative mutant of Ikappa B prevented protection by IL-1. Protection from CD95-induced apoptosis by IL-1 might also affect the activity of those chemotherapeutic drugs that exert their cytotoxic effect via the CD95/CD95L system (3-5). This assumption is also supported by the observation that activation of NFkappa B protects cells against apoptosis induced by the cytostatic drug daunorubicin (35).

Because NFkappa B rescues cells from death induced by TNFalpha (35-38), TRAIL (13), ionizing radiation (35), chemotherapeutic drugs (35), and, as demonstrated in this study, from CD95-mediated cell death, NFkappa B appears to protect from apoptosis in general. Thus, it was quite surprising to observe that IL-1 did not protect but even enhanced apoptosis induced by UV radiation.

Recently it was reported that CD95 is critically involved in UV-mediated apoptosis (24, 39, 40). UV radiation can directly activate the death receptor by inducing functional aggregation of CD95 (24, 39). Inhibition of CD95 clustering following UV exposure reduces but does not completely block apoptosis (24), implying that besides the CD95 pathway other mechanisms must be involved as well. This assumption is supported by the present findings: if UV-induced apoptosis was to be exclusively mediated by CD95, both CD95- and UV-induced apoptosis would be inhibitable by the same interventions. In this case, IL-1 should have protected KB and HaCaT cells not only from CD95- but also from UV-induced apoptosis.

According to recent reports (30, 33, 41, 42), NFkappa B appears to exert its antiapoptotic effects via the induction of antiapoptotic proteins, including c-IAP1, c-IAP2, X-linked IAP, and IEX-1L. Therefore, we were interested in the effect IL-1 may exert on the expression of IAPs in cells exposed either to TRAIL, CD95-Ab, or UV light. Intracellular protein measurements revealed that all three apoptotic stimuli reduced levels of c-IAP1 and c-IAP2, although at different levels. c-IAP1 and c-IAP2 appear to exert their antiapoptotic activity by specifically binding to the terminal effector domains of caspase-3 and -7 (43). In contrast to the mode of action of these proteins, little is known about how c-IAPs are regulated, except that they are under control of NFkappa B and that c-IAP2 can exert a positive feedback control on NFkappa B via an Ikappa B targeting mechanism (44). This study for the first time demonstrates negative regulation of c-IAP expression by apoptotic stimuli. Because this was assessed only by determining the protein expression, we do not as yet know whether this inhibition is transcriptionally regulated. Although the mechanisms by which c-IAPs are down-regulated remain to be determined, this phenomenon might be of relevance for the execution of apoptosis. CD95- and TRAIL-mediated down-regulation of both c-IAP1 and c-IAP2 was partially antagonized by IL-1. Thus, induction of c-IAP1 and c-IAP2 might be the mechanism by which IL-1 rescues cells from CD95- and TRAIL-induced apoptosis. In contrast, UV-mediated down-regulation of c-IAPs was not restored by IL-1 but even further enhanced slightly. Although we do not yet know the mechanism by which IL-1 affects c-IAP expression in such a different way, the present data indicate that whether a signal acts in an antiapoptotic way or not does not only depend on the signal itself but also on the stimulus causing apoptosis.

The apoptotic effects of TNFalpha on most cells can only be observed when protein synthesis is blocked, suggesting that de novo protein synthesis protects cells by induction of antiapoptotic genes (35). Keratinocytes are able to release TNFalpha (18), and we therefore hypothesized that enhancement of UV-induced apoptosis by IL-1 may be mediated by the autocrine release of TNFalpha . Because protective c-IAPs are down-regulated upon UV-exposure, under these conditions the apoptotic effect of TNFalpha could dominate the activation of NFkappa B. Indeed, the enhancing effect of IL-1 on UV-induced apoptosis was completely reversed when the experiment was performed in the presence of an antibody, which blocks the TNF-receptor type 1. Accordingly, excessively enhanced levels of TNFalpha were detected when cells were exposed to UV radiation in the presence of IL-1. Neither TRAIL nor CD95-Ab synergized with IL-1 to induce TNFalpha release from KB or HaCaT cells. Thus, this observation is compatible with our hypothesis that down-regulation of c-IAPs preconditions the cells for the killing effect of TNFalpha .

Taken together, the present study demonstrates that IL-1 can exert diverse effects on apoptosis. TRAIL- and CD95-mediated apoptosis is significantly reduced by IL-1 via activation of NFkappa B, whereas UV-mediated apoptosis is remarkably enhanced via the autocrine release of TNFalpha . Thus, IL-1 cannot be regarded as an antiapoptotic cytokine in general. Furthermore, these findings suggest that whether a stimulus affects apoptosis in a positive or negative way does not exclusively depend on the nature of the stimulus itself but also on the signal that induces apoptosis. As demonstrated here, completely opposite effects can be obtained in different apoptosis systems.

    ACKNOWLEDGEMENT

We thank J. Bückmann and P. Wissel for preparing the graphs and A. Mehling for critically reading the mansucript. We are grateful to Dr. N. Fusenig for providing HaCaT cells.

    FOOTNOTES

* This work was supported by grants from Interdisziplinäres Zentrum für Klinische Forschung Münster (IZKF/D12), the German Research Foundation (Schw 625/1-3), and the European Community (ENV4-CT97-0556). This work is part of the PhD thesis of G. K.-W.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Dermatology, University Münster, Von-Esmarchstrasse 56, D-48149 Münster, Germany. Tel.: 49-251-83-56565; Fax: 49-251-83-58579; E-mail: schwtho@uni-muenster.de.

    ABBREVIATIONS

The abbreviations used are: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; CD95-Ab, agonistic anti-CD95-antibody; CD95L, CD95 ligand; IAP, inhibitor of apoptosis protein; IL-1, interleukin-1; NFkappa B, nuclear factor-kappa B; PARP, poly(ADP-ribose) polymerase; TNF, tumor necrosis factor; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Cohen, J. J. (1993) Immunol. Today 14, 126-130[Medline] [Order article via Infotrieve]
2. Korsmeyer, S. J., and Greenberg, P. D. (1998) Curr. Opin. Immunol. 10, 543-544[CrossRef]
3. Friesen, X., Herr, I., Krammer, P. H., and Debatin, K. M. (1996) Nat. Med. 2, 574-577[CrossRef][Medline] [Order article via Infotrieve]
4. Müller, M., Strand, S., Hug, H., Heinermann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. (1997) J. Clin. Invest. 99, 403-413[Medline] [Order article via Infotrieve]
5. Gamen, S., Anel, A., Lasierra, P., Alava, M. A., Martrinex-Lorenzo, M. J., Pineiro, A., and Naval, J. (1997) FEBS Lett. 417, 360-364[CrossRef][Medline] [Order article via Infotrieve]
6. Haq, R., and Zanke, B. (1998) Cancer Metastasis Rev. 17, 233-239[CrossRef][Medline] [Order article via Infotrieve]
7. Bold, R. J., Termuhlen, P. M., and McConkey, D. J. (1997) Surg Oncol. 6, 133-142[CrossRef][Medline] [Order article via Infotrieve]
8. Hughes, S. J., Nambu, Y., Soldes, O. S., Hamstra, D., Rehemtulla, A., Iannettoni, M. D., Orringer, M. B., and Beer, D. G. (1997) Cancer Res. 75, 5571-5578
9. Nambu, Y., Hughes, S. J., Rehemtulla, A., Hamstra, D., Orringer, M. B., and Beer, D. G. (1998) J. Clin. Invest. 101, 1102-1110[Medline] [Order article via Infotrieve]
10. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. (1995) Immunity 3, 673-682[CrossRef][Medline] [Order article via Infotrieve]
11. Pitti, R. M., Marsters, S. C., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. (1996) J. Biol. Chem. 271, 12687-12690[Abstract/Free Full Text]
12. Peter, M. E., and Krammer, P. H. (1998) Curr. Opin. Immunol. 10, 545-551[CrossRef][Medline] [Order article via Infotrieve]
13. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al.. (1999) Nat. Med. 5, 157163
14. Kothny-Wilkes, G., Kulms, D., Pöppelmann, B., Luger, T. A., Kubin, M., and Schwarz, T (1998) J. Biol. Chem. 273, 29247-29253[Abstract/Free Full Text]
15. Luger, T. A., and Schwarz, T. (1992) in Pharmacology of the Skin (Mukhtar, H., ed) , pp. 283-313, CRC Press, Boca Raton, FL
16. Durum, S. K., Oppenheim, J. J., and Neta, R. (1990) in Immunophysiology. The Role of Cells and Cytokines in Immunity and Inflammation (Oppenheim, J. J. , and Shevach, E. M., eds) , pp. 210-225, Oxford University Press, New York, Oxford
17. Boukamp, P., Petrussevska, R. T, Breikreutz, D., Hornung, J., Markham, A., and Fusenig, N. E. (1988) J. Cell Biol. 106, 761-771[Abstract/Free Full Text]
18. Köck, A., Schwarz, T., Kirnbauer, R., Urbanski, A., Perry, P., Ansel, J. C., and Luger, T. A. (1990) J. Exp. Med. 172, 1609-1614[Abstract/Free Full Text]
19. Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G., and Rauch, C. T. (1997) EMBO J. 16, 5386-5397[CrossRef][Medline] [Order article via Infotrieve]
20. Traenckner, E. B.-M., Wilk, S., and Baeuerle, P. A. (1995) EMBO J. 14, 2876-2838[Medline] [Order article via Infotrieve]
21. Melkonyan, H., Sorg, C., and Klempt, M. (1996) Nucleic Acids Res. 24, 4356-4357[Abstract/Free Full Text]
22. Enari, M., Hug, H., and Nagata, S. (1995) Nature 375, 78-81[CrossRef][Medline] [Order article via Infotrieve]
23. Schlegel, J., Peter, I., Orrenius, S., Miller, D. K., Thornberry, N. A., Yamin, T. T., and Nicholson, D. W. (1996) J. Biol. Chem. 271, 1841-1844[Abstract/Free Full Text]
24. Aragane, Y., Kulms, D., Metze, D., Kothny, G., Pöppelmann, B., Luger, T. A., and Schwarz, T. (1998) J. Cell Biol. 140, 171-182[Abstract/Free Full Text]
25. Mariani, S. M., Matiba, B., Armandola, E. A., and Krammer, P. H. (1997) J. Cell Biol. 137, 221-229[Abstract/Free Full Text]
26. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al.. (1995) Nature 376, 37-43[CrossRef][Medline] [Order article via Infotrieve]
27. Lazebnik, Y. A., Kaufmann, S. H., Desnoyer, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347[CrossRef][Medline] [Order article via Infotrieve]
28. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) Cell 78, 773-785[CrossRef][Medline] [Order article via Infotrieve]
29. Traenckner, E. B.-M., Wilk, S., and Baeuerle, P. A. (1994) EMBO J. 13, 5433-544129[Medline] [Order article via Infotrieve]
30. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. (1998) Science 281, 1680-1683[Abstract/Free Full Text]
31. Hale, A. J., Smith, C. A., Sutherland, L. C., Stoenman, V. E. A., Longthorne, V. L., Culhane, A. C., and Williams, G. T. (1996) Eur. J. Biochem. 236, 1-26[Medline] [Order article via Infotrieve]
32. Barinaga, M. (1996) Science 273, 735-737[Free Full Text]
33. Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J. A., Binder, B. R., and Lipp, J. (1998) J. Exp. Med. 188, 211-216[Abstract/Free Full Text]
34. Haridas, V., Drany, B. G., Natarajan, K., Heller, R., and Aggarwal, B. B. (1998) J. Immunol 160, 3152-3162[Abstract/Free Full Text]
35. Wang, C.-Y., Mayo, M. W., and Baldwin, A. S., Jr. (1996) Science 274, 784-787[Abstract/Free Full Text]
36. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
37. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576[CrossRef][Medline] [Order article via Infotrieve]
38. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
39. Rehemtulla, A., Hamilton, C. A., Chinnaiyan, A. M., and Dixit, V. M. (1997) J. Biol. Chem. 272, 25783-25786[Abstract/Free Full Text]
40. Leverkus, M., Yaar, M., and Gilchrest, B. A. (1997) Exp. Cell Res. 232, 255-262[CrossRef][Medline] [Order article via Infotrieve]
41. Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997) Nature 388, 300-304[CrossRef][Medline] [Order article via Infotrieve]
42. Wu, M. X., Ao, Z., Prasad, K. V. S., Wu, R., and Schlossman, S. F. (1998) Science 281, 998-1001[Abstract/Free Full Text]
43. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997) EMBO J. 16, 6914-6925[CrossRef][Medline] [Order article via Infotrieve]
44. Chu, Z. L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., and Ballard, D. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10057-10062[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
L. M. Sedger, S. R. Osvath, X.-M. Xu, G. Li, F. K.-M. Chan, J. W. Barrett, and G. McFadden
Poxvirus Tumor Necrosis Factor Receptor (TNFR)-Like T2 Proteins Contain a Conserved Preligand Assembly Domain That Inhibits Cellular TNFR1-Induced Cell Death.
J. Virol., September 1, 2006; 80(18): 9300 - 9309.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Maeda, S. W. Schneider, M. Kojima, S. Beissert, T. Schwarz, and A. Schwarz
Enhanced photocarcinogenesis in interleukin-12-deficient mice.
Cancer Res., March 15, 2006; 66(6): 2962 - 2969.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Schwarz, A. Maeda, S. Stander, H. van Steeg, and T. Schwarz
IL-18 reduces ultraviolet radiation-induced DNA damage and thereby affects photoimmunosuppression.
J. Immunol., March 1, 2006; 176(5): 2896 - 2901.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Maggio-Price, H. Bielefeldt-Ohmann, P. Treuting, B. M. Iritani, W. Zeng, A. Nicks, M. Tsang, D. Shows, P. Morrissey, and J. L. Viney
Dual Infection with Helicobacter bilis and Helicobacter hepaticus in P-Glycoprotein-Deficient mdr1a-/- Mice Results in Colitis that Progresses to Dysplasia
Am. J. Pathol., June 1, 2005; 166(6): 1793 - 1806.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Poppelmann, K. Klimmek, E. Strozyk, R. Voss, T. Schwarz, and D. Kulms
NF{kappa}B-dependent Down-regulation of Tumor Necrosis Factor Receptor-associated Proteins Contributes to Interleukin-1-mediated Enhancement of Ultraviolet B-induced Apoptosis
J. Biol. Chem., April 22, 2005; 280(16): 15635 - 15643.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. D'Errico, M. Teson, A. Calcagnile, T. Nardo, N. De Luca, C. Lazzari, S. Soddu, G. Zambruno, M. Stefanini, and E. Dogliotti
Differential Role of Transcription-Coupled Repair in UVB-Induced Response of Human Fibroblasts and Keratinocytes
Cancer Res., January 15, 2005; 65(2): 432 - 438.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. D. Southall, J. S. Isenberg, H. Nakshatri, Q. Yi, Y. Pei, D. F. Spandau, and J. B. Travers
The Platelet-activating Factor Receptor Protects Epidermal Cells from Tumor Necrosis Factor (TNF) alpha and TNF-related Apoptosis-inducing Ligand-induced Apoptosis through an NF-kappa B-dependent Process
J. Biol. Chem., November 30, 2001; 276(49): 45548 - 45554.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. D. S. Jean, C. Debbasch, M. Rahmani, F. Brignole, G. Feldmann, J.-M. Warnet, and C. Baudouin
Fas- and Interferon {gamma}-Induced Apoptosis in Chang Conjunctival Cells: Further Investigations
Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2531 - 2543.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
D. Bernard, B. Quatannens, B. Vandenbunder, and C. Abbadie
Rel/NF-kappa B Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1
J. Biol. Chem., July 13, 2001; 276(29): 27322 - 27328.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Kulms, B. Poppelmann, and T. Schwarz
Ultraviolet Radiation-induced Interleukin 6 Release in HeLa Cells Is Mediated via Membrane Events in a DNA Damage-independent Way
J. Biol. Chem., May 12, 2000; 275(20): 15060 - 15066.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow